НовостиBenzingaUBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71 UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71 Benzinga 2026.10.15 21:57 (GMT+0) Открыть на Benzinga Другие новости